DOM-CR, or DOM/CR, an acronym of "DOM-conformationally restrained", is a tetrahydroisoquinoline (THIQ) and cyclized phenethylamine related to the psychedelics DOM and 2C-D. It is a cyclized THIQ analogue of DOM and 2C-D.
DOM-CR shows more than 20-fold reduced affinity for the serotonin 5-HT<sub>2A</sub> receptor compared to DOM (K<sub>i</sub> = 2,150nM vs. 100nM, respectively). In contrast to DOM, DOM-CR does not substitute for DOM in rodent drug discrimination tests, suggesting that it lacks psychedelic effects. Similarly, DOM-CR does not substitute for dextroamphetamine or MDMA, suggesting that it likewise lacks stimulant or entactogenic effects. However, DOM-CR does substitute for TDIQ (MDTHIQ), a selective ñ<sub>2</sub>-adrenergic receptor ligand. At high doses, DOM-CR produces behavioral disruption in drug discrimination tests. In contrast to DOM and amphetamine, DOM-CR does not produce hyperlocomotion in rodents.
DOM-CR was first described in the scientific literature by Richard Glennon and colleagues by 1996.
Other cyclized THIQ analogues of psychoactive phenethylamines have also been developed and characterized. These include AMPH-CR (THIQ), METH-CR (N-methyl-THIQ), TDIQ (MDTHIQ, MDA-CR), TDMIQ (MDMTHIQ, MDMA-CR), N-methyl-DOM-CR (Beatrice-CR), DOB-CR, and PMMA-CR. Conformational restriction of stimulant, hallucinogen, and/or entactogen phenethylamines into THIQ analogues, like the preceding compounds, usually reduces or abolishes their associated effects as well as their affinities for monoamine transporters and/or serotonin 5-HT<sub>2</sub> receptors. However, it does not necessarily remove all pharmacological activity, as evidenced by some THIQs interacting with ñ<sub>2</sub>-adrenergic receptors as well as serotonin 5-HT<sub>1D</sub>, 5-HT<sub>6</sub>, and/or 5-HT<sub>7</sub> receptors and producing behavioral effects in animals.
Other cyclized analogues of DOM and related psychedelics include DOM-AT, DOM-AI, DMCPA, TFMBOX, jimscaline, TCB-2, LPH-5, and ZC-B.